Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CABALETTA BIO INC.
CABA | US
3.20
USD0.07
2.24%
CABA | US
About CABALETTA BIO INC.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
3.20
Open
3.19
High
3.29
Low
3.15
Cabaletta Bio Inc. a clinical-stage biotechnology company focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201 a 4-1BB-containing CD19-CAR T investigational therapy for the treatment of severe autoimmune diseases; PLA2R-CAART a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics Inc. and changed its name to Cabaletta Bio Inc. in August 2018. Cabaletta Bio Inc. was incorporated in 2017 and is headquartered in Philadelphia Pennsylvania.
View LessCABA | US
Risk
74.8
Sharpe
1.57
Luna's Score
60/100
Recommendation
Hold
Luna says (CABA | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
81.0%1 month
74.8%3 months
94.0%6 months
112.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.19
Debt to equity
0.04
Debt to assets
0.03
Ent. to EBITDA
-3.44
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-98.61M
MarketCap
156.32M
MarketCap(USD)
156.32M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-48.16
Short ratio
5.41
Short perc.
11.26
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.83
Range1M
0.83
Range3M
1.74
Volumes: Market Activity
Rel. volume
0.76
Price X volume
4.77M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.44 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.19 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 93.96 | - | Riskier |
| Debt to Equity | 0.04 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 156.32M | - | Emerging |
